Image (Tascenso 01)
Tascenso Odt Tablet, Orally Disintegrating
Product Images NDC 70709-062
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tascenso Odt (NDC 70709-062). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cycle Pharmaceuticals Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Tascenso 02)
Chemical structure diagram of Fingolimod Lauryl Sulfate showing the arrangement of its molecular components including hydroxyl groups, ammonium, and sulfate functional groups attached to a hydrocarbon chain.*
Figure 1 (Tascenso 03)
A line chart showing the percentage of patients with three-month confirmed progression over time (days) comparing Fingolimod 0.5 mg versus placebo. The graph indicates lower progression rates for the Fingolimod group (18%) compared to placebo (24%) over a period of approximately 720 days.*
Principal Display Panel (Tascenso 04)
Principal Display Panel (0.25 mg Tablet Blister Pack Carton)
TASCENSO ODT 0.25 mg orally disintegrating tablets packaging label. The box contains 30 tablets, organized in 3 blister cards of 10 tablets each. The label shows active ingredient fingolimod, manufacturer Cycle Pharmaceuticals Ltd, and usage instructions including storage conditions and how to remove tablets from blister packaging. The design features the Cycle Pharma logo and NDC 70709-062-30.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
